Discontinued — last reported Q3 '20
Amgen Finite-Lived Intangible Assets - Expected Amortization Expense (Year Four) decreased by 3.4% to $2.80B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 3.4%, from $2.90B to $2.80B.
A decrease suggests lower future non-cash charges, potentially boosting reported net income, while an increase reflects significant recent asset acquisitions.
This represents the projected non-cash expense associated with the amortization of finite-lived intangible assets, such...
Standard disclosure for pharmaceutical companies with significant M&A activity and R&D pipelines.
finite_lived_intangible_assets_amortization_year_4| Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.80B | $2.10B | $2.10B | $2.10B | $2.90B | $2.90B | $2.90B | $2.80B | $2.90B | $2.80B |
| QoQ Change | — | +16.7% | +0.0% | +0.0% | +38.1% | +0.0% | +0.0% | -3.4% | +3.6% | -3.4% |
| YoY Change | — | — | — | +16.7% | +38.1% | +38.1% | +38.1% | -3.4% | +0.0% | -3.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.